NCT03155009 - A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

September 26, 2019

Study Completion Date

September 26, 2019

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Alectinib

600 mg orally BID with food

Trial Locations (16)

13915

Hôpital Nord - AP-HM Marseille#, Marseille

14076

Centre Francois Baclesse; Comite 3, Caen

25030

Hopital Jean Minjoz; Pneumologie, Besançon

29609

Hopital Augustin Morvan; Oncologie Thoracique, Brest

31100

CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse

33600

CHU de Bordeaux, Pessac

35033

Hopital de Pontchaillou; Service de Pneumologie, Rennes

38700

Hôpital Nord Michallon; Pneumologie, La Tronche

49933

CHU Angers, Angers

57070

Hopital Robert Schuman; Pneumologie, Vantoux

59000

CHRU Lille Service de Pneumologie et Oncologie Thoracique, Lille

68070

Hopital Emile Muller;Pneumologie, Mulhouse

75005

Institut Curie, Paris

75970

Hopital Tenon;Pneumologie, Paris

76031

CHU de Rouen - Hôpital Charles Nicolle, Rouen

94010

Centre Hospitalier Intercommunal; Service de Pneumologie, Créteil

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY